S100A6 and endometrial cancer: In contrast, a large proportion of in vitro evidence suggests that the absence or reduced expression of PR-B, but not PR-A, might result in the failure of progesterone treatment; this is called progesterone resistance, and it leads to aberrant PR-B-mediated signaling in endometrial cancer cells11.